This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Novartis Pharma AG, Switzerland.
Reference
Regnier SA, et al. Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective. ClinicoEconomics and Outcomes Research : 6 May 2015. Available from: URL: http://dx.doi.org/10.2147/CEOR.S82556
Rights and permissions
About this article
Cite this article
Ranibizumab for DME in the UK: better outcomes, lower cost. PharmacoEcon Outcomes News 728, 26 (2015). https://doi.org/10.1007/s40274-015-2146-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2146-2